Globus Medical's Excelsius3D™ imaging system receives CE marking for European market

AUDUBON, Pa., Sept. 03, 2026 /CourierPR/ -- Globus Medical, a leading musculoskeletal technology company, has announced the CE marking of its Excelsius3D™ imaging system, marking a significant expansion of its Excelsius™ Ecosystem. This system, now available for commercial sale in the European Union and the United Kingdom, combines 3D cone-beam computed tomography (CT), 2D fluoroscopy, and digital radiography in a single, mobile platform. The Excelsius3D™ integrates seamlessly with the company’s ExcelsiusGPS™ robotic navigation system, enhancing intraoperative imaging and navigation capabilities.

Designed for intraoperative use, Excelsius3D™ offers surgeons and operating room teams multiple imaging modalities in a compact, easy-to-position format. Its omnidirectional wheels facilitate smooth movement within the operating room, while the system’s comprehensive imaging capabilities support a wide range of surgical applications. The CE marking is a crucial step in expanding Globus Medical’s presence in the European market, providing surgeons with advanced tools to improve patient outcomes.

"Obtaining the CE mark for Excelsius3D™ is an important milestone in the continued growth of our Excelsius™ Ecosystem," said Keith Pfeil, President and CEO of Globus Medical. "We are committed to bringing innovative technologies to surgeons worldwide, and this step further enhances the capabilities of our platform by integrating advanced imaging with robotic navigation."

Norbert Johnson, Chief Technology Officer of Globus Medical, added, "Excelsius3D™ was designed with the goal of integrating advanced imaging capabilities into a mobile platform that can seamlessly fit into the surgical workflow. Its integration with ExcelsiusGPS™ represents a significant step towards connecting imaging, navigation, and robotics within our ecosystem, providing surgeons with comprehensive tools to support their procedures."

The Excelsius3D™ system received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2021. With the CE marking, Globus Medical will now commence commercialization of the system in the European Union and United Kingdom markets. The system is designed to function both as a standalone intraoperative imaging platform and as an integrated component of the Excelsius™ Ecosystem with ExcelsiusGPS™, offering hospitals and surgical teams flexibility in leveraging its advanced imaging capabilities.

Globus Medical, established as a global leader in musculoskeletal technology, continues to innovate with a focus on addressing unmet clinical needs and improving patient care. The company’s commitment to advancing care through spine, orthopedic trauma, joint reconstruction, and enabling technologies underscores its dedication to delivering cutting-edge solutions to the medical community.